TMCnet News
Kurin Inc. CEO Addresses Patent Infringement Lawsuit Brought by Magnolia MedicalKurin Inc., the inventor and manufacturer of Kurin® blood culture collection sets, responded to a patent-infringement lawsuit brought against Kurin by Magnolia Medical. With its innovative design the Kurin Lock® has been a disruptive technology in the market, allowing Kurin to quickly engage hospitals that prefer its FDA 510(k) cleared device. With a small, intuitive design, the Kurin Lock is easy to use and suitable for a wide range of applications, including pediatrics. From the beginning, Magnolia attacked Kurin's design claiming that it did not divert enough volume or sufficiently isolate diverted blood. Now that the Kurin Lock has been proven in clinical use and hospitals are switching from Steripath to the Kurin Lock, Magnolia is claiming patent infringement. "The timing of this suit is not a coincidence," said Bob Rogers, CEO of Kurin and inventor of the Kurin Lock. "For years, Magnolia has sold their Steripath product without FDA clearance. It is a large, cumbersome device that is not intuitive, and is unsuitable for use in pediatrics, so it is not surprising that Magnolia has failed to gain market traction." Despite their prior claims that the Kurin Lock design is ineffective, Magnolia now asserts that it invented the Kurin device. "It is illogical. Why would Magnolia launch and continue to sell their Rube Goldberg contraption if they had conceived the simple, intuitive design of the Kurin Lock?" asked Rogers. Continuing, Rogers said, "We respect the intellectual property rights of others. The U.S. Patent Office has found the design of the Kurin Lock to be novel when compared to Magnolia's patents, and worthy of patent protection. The Kurin Lock does not infringe any Magnolia patent and we are confident that this position will be proven in court. Our team has significant resources and a track record of success in patent litigation to see this baseless suit through, however long it takes." About Kurin Inc. Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190212005124/en/ |
